Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Thoracic Paravertebral Block in the Reduction of Acute Post-surgical Pain in Patients With Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02609321
Recruitment Status : Completed
First Posted : November 20, 2015
Last Update Posted : December 26, 2016
Sponsor:
Information provided by (Responsible Party):
Instituto de Cancerología S.A.

Brief Summary:
Surgical treatment of breast cancer is frequently associated with postoperative pain in the surgical area. Persistent pain after breast cancer management has considerable negative effects on the quality of life of survivors. The aim of this trials is to evaluate the efficacy of thoracic paravertebral block with bupivacine 0.5% in reducing the acute pain postmastectomy compare with surgical wound infiltration with bupivacaine 0.5%.

Condition or disease Intervention/treatment Phase
Breast Cancer Procedure: Thoracic Paravertebral Block Procedure: Surgical Wound Infiltration Phase 3

Detailed Description:

Surgical treatment of breast cancer is frequently associated with postoperative pain in the surgical area, restricted movement of the ipsilateral upper limb and increased risk of chronic pain. This usually occurs even though management with analgesics commonly used in the postoperative period. Properly treatment of acute postoperative pain have essential implications: improving the general welfare of patients, can better withstand future medical interventions, facilitating recovery in the short and long term and is believed to have positive impact on survival from cancer.

Persistent pain after breast cancer management has considerable negative effects on the quality of life of survivors. Several risks factors have been described in preoperative, intra-operative and postoperative periods of persistent or chronic pain. In the postoperative period the most important risk factor is the severity of acute pain. For this, pain relief is an essential component of care of patients undergoing breast cancer surgery. Current evidence suggests that treatment of acute postoperative pain reduces the risk of persistent or chronic pain syndrome. The surgical wound infiltration with local anesthesia has been used routinely in patients managed at the Cancer Institute and Clinica Las Americas and is described as a safe and accessible procedure for the management of acute postoperative pain. Paravertebral block represents an interesting alternative in the management of perioperative pain, often used for breast surgery, hernia repair and thoracotomy in children and adults. Although complications associated with blocking are uncommon, the implementation of Ultrasound-guided approach has become the standard for performing said method.

Such considerations have led us to evaluate whether patients with breast cancer who are undergoing mastectomy, thoracic paravertebral block could be better in relief acute pain in comparison with surgical wound infiltration with local anesthesia. This will be studied by controlled randomized to one of two intervention groups (paravertebral block or local anesthesia with infiltration of the surgical wound) allocation trial. In all patients, general anesthesia and routine postoperative analgesic is used.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Thoracic Paravertebral Block vs Local Anesthesia of the Surgical Wound in Reduction of Acute Post-surgical Pain in Patients With Breast Cancer. Controlled Phase III, Randomized, Single-blind, Superiority Clinical Trial.
Study Start Date : November 2015
Actual Primary Completion Date : August 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Thoracic Paravertebral Block
to identify the thoracic T3, a parallel line 2.5 cm from the spinous process is drawn and in this place the ultrasound sensor is placed. Ultrasonograph image identifies the transverse process, the intercostal cost-transverse ligament, the pleura and lung. We proceed to insert a needle between the two corresponding transverse processes and positions after passing the cost-ligament posterior intercostal and transverse to the parietal pleura. After negative aspiration for blood, 0.5% bupivacaine anesthetic is administered at doses of 1.5 mg/kg slowly. The volume is defined by the anesthesiologist. The injection of anesthetic is displayed, as well as confirmation of the correct location of the needle because the volume injected above pushes the pleura.
Procedure: Thoracic Paravertebral Block
Thoracic paravertebral block at T3 level with bupivacaine 0.5%, dosis 1.5mg/Kg

Active Comparator: Surgical Wound Infiltration
before the close of the skin, it proceeds to infiltrate the subcutaneous tissue and skin with 0.5% bupivacaine at doses of 1.5 mg/kg, generating the widest possible dissemination of the bupivacaine in the surgical area.
Procedure: Surgical Wound Infiltration
Surgical wound infiltration on the skin and subcutaneous tissue in surgical area with bipivacaine 0.5%, dosis 1.5mg/kg




Primary Outcome Measures :
  1. Acute post-surgical pain at rest and motion [ Time Frame: 24 hours ]
    Acute pain at rest and in motion at 2, 4, 6, 12 and 24 hours post operative, measured by a visual analog scale (0-100 mm) for the paravertebral block group compared with the surgical wound infiltration group.


Secondary Outcome Measures :
  1. Adverse Events [ Time Frame: 2 months ]
    Compare the frequency and severity of adverse events in both groups

  2. Total doses of opioids [ Time Frame: 24 hours ]
    Compare the total dose of self-administered opioids analgesics for the first 24 hours

  3. Time to the first dose of opioids [ Time Frame: 24 hours ]
    Compare the time to first dose of opioids analgesics in both groups

  4. Post-mastectomy pain syndrome [ Time Frame: 2 months ]
    Compare the frequency of diagnosis of Post-mastectomy pain syndrome (SDP) two months after breast surgery in both groups

  5. Quality of life [ Time Frame: 2 months ]
    Estimate the changes in the quality of life of patients after two months after breast surgery in both groups



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Women older than 18 years.
  2. Diagnosis of breast cancer requiring major elective surgery: unilateral mastectomy with or without axillary dissection; with or without axillary sentinel node biopsy; with or without immediate breast reconstruction.
  3. Willingness to participate in the study during the follow-up period.

Exclusion Criteria:

  1. Metastatic breast carcinoma; tumor involvement of contra lateral breast or armpit determined by clinical or paraclinical studies.
  2. Medical History of coagulopathy.
  3. Consumption of anticoagulants.
  4. Contraindication to NSAIDs or opioids.
  5. Allergy to local anesthetics of amide type.
  6. Infection a interventions sites (paravertebral block or area affected breast surgical wound)
  7. Pregnancy and lactation.
  8. BMI>35.
  9. Parkinson's disease, Alzheimer's disease or other diseases that affect the mental or motor sphere.
  10. Double mastectomy or mastectomy history of previous ipsilateral to the current episode.
  11. Preoperative risk classification ASA IV-V.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02609321


Locations
Layout table for location information
Colombia
Instituto de Cancerología IDC Las Américas
Medellín, Antioquia, Colombia
Sponsors and Collaborators
Instituto de Cancerología S.A.
Investigators
Layout table for investigator information
Principal Investigator: Fernando Herazo, MD, MSc Instituto de Cancerología IDC Las Américas
Principal Investigator: Hector I García, MD, MPH, MSc Instituto de Cancerología IDC Las Américas
Principal Investigator: Jorge A Egurrola, MD Instituto de Cancerología IDC Las Américas

Publications of Results:
Layout table for additonal information
Responsible Party: Instituto de Cancerología S.A.
ClinicalTrials.gov Identifier: NCT02609321    
Other Study ID Numbers: IDC0001
First Posted: November 20, 2015    Key Record Dates
Last Update Posted: December 26, 2016
Last Verified: December 2016
Keywords provided by Instituto de Cancerología S.A.:
Paravertebral
Single injection
Breast surgery
Analgesia
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Bupivacaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents